Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 568


13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Jun 20. doi: 10.1002/gcc.22645. [Epub ahead of print]


Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Jun 13. pii: S0302-2838(18)30423-8. doi: 10.1016/j.eururo.2018.05.034. [Epub ahead of print]


CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.

Drenckhan A, Freytag M, Supuran CT, Sauter G, Izbicki JR, Gros SJ.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1024-1033. doi: 10.1080/14756366.2018.1475369.


PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.


Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer.

Neubauer E, Latif M, Krause J, Heumann A, Armbrust M, Luehr C, Fraune C, Hube-Magg C, Kluth M, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe RS, Thederan I, Schlomm T, Büscheck F.

Exp Mol Pathol. 2018 May 24;105(1):50-56. doi: 10.1016/j.yexmp.2018.05.006. [Epub ahead of print]


Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes.

Münscher A, Prochnow S, Gulati A, Sauter G, Lörincz B, Blessmann M, Hanken H, Böttcher A, Clauditz TS.

Clin Oral Investig. 2018 Apr 18. doi: 10.1007/s00784-018-2444-8. [Epub ahead of print]


Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C.

World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9.


Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat SF, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M.

Transl Androl Urol. 2017 Dec;6(6):1018-1026. doi: 10.21037/tau.2017.11.10.


Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.

Kluth M, Jung S, Habib O, Eshagzaiy M, Heinl A, Amschler N, Masser S, Mader M, Runte F, Barow P, Frogh S, Omari J, Möller-Koop C, Hube-Magg C, Weischenfeldt J, Korbel J, Steurer S, Krech T, Huland H, Graefen M, Minner S, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Nov 11;8(65):108923-108935. doi: 10.18632/oncotarget.22408. eCollection 2017 Dec 12.


High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.


EZH2 overexpression in head and neck cancer is related to lymph node metastasis.

Nienstedt JC, Schroeder C, Clauditz T, Simon R, Sauter G, Muenscher A, Blessmann M, Hanken H, Pflug C.

J Oral Pathol Med. 2018 Mar;47(3):240-245. doi: 10.1111/jop.12673. Epub 2018 Jan 22.


IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.

Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, Wilczak W.

Oncol Rep. 2018 Jan;39(1):3-12. doi: 10.3892/or.2017.6072. Epub 2017 Nov 2.


PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Jul 10;8(39):65566-65576. doi: 10.18632/oncotarget.19217. eCollection 2017 Sep 12.


FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.

Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.

Carcinogenesis. 2017 Dec 7;38(12):1180-1187. doi: 10.1093/carcin/bgx105.


Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.

Person F, Wilczak W, Hube-Magg C, Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S, Jacobsen F.

Tumour Biol. 2017 Oct;39(10):1010428317712166. doi: 10.1177/1010428317712166.


Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.

Clauditz TS, Böttcher A, Hanken H, Borgmann K, Sauter G, Wilczak W, Grob T, Münscher A.

J Cancer Res Clin Oncol. 2018 Jan;144(1):53-61. doi: 10.1007/s00432-017-2528-x. Epub 2017 Oct 11.


Expression of Epithelial-Mesenchymal Transition Regulating Transcription Factors in Head and Neck Squamous Cell Carcinomas.

Göppel J, Möckelmann N, Münscher A, Sauter G, Schumacher U.

Anticancer Res. 2017 Oct;37(10):5435-5440.


Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy.

Leyh-Bannurah SR, Karakiewicz PI, Dell'Oglio P, Briganti A, Schiffmann J, Pompe RS, Sauter G, Schlomm T, Heinzer H, Huland H, Graefen M, Budäus L.

Clin Genitourin Cancer. 2017 Aug 31. pii: S1558-7673(17)30246-X. doi: 10.1016/j.clgc.2017.08.005. [Epub ahead of print]


Mitochondrial mutations drive prostate cancer aggression.

Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, McPherson JD, van der Kwast T, Korbel J, Schlomm T, Bristow RG, Boutros PC.

Nat Commun. 2017 Sep 22;8(1):656. doi: 10.1038/s41467-017-00377-y.


High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.

Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F.

Prostate. 2017 Nov;77(15):1528-1538. doi: 10.1002/pros.23431. Epub 2017 Sep 19.


Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N.

Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.


Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.

Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann SA, Burdak-Rothkamm S.

BMC Cancer. 2017 Jul 26;17(1):504. doi: 10.1186/s12885-017-3489-9.


High-level βIII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome.

Nienstedt JC, Gröbe A, Clauditz T, Simon R, Muenscher A, Knecht R, Sauter G, Moebius C, Blessmann M, Heiland M, Pflug C.

J Oral Pathol Med. 2017 Nov;46(10):986-990. doi: 10.1111/jop.12607. Epub 2017 Jul 9.


Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study.

Weixler B, Viehl CT, Warschkow R, Guller U, Ramser M, Sauter G, Zuber M.

JAMA Surg. 2017 Oct 1;152(10):912-920. doi: 10.1001/jamasurg.2017.1514.


Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.


Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?

Gebauer F, Kemper M, Sauter G, Prehm P, Schumacher U.

PLoS One. 2017 Jun 5;12(6):e0178703. doi: 10.1371/journal.pone.0178703. eCollection 2017.


Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2017 May 17;7(1):2056. doi: 10.1038/s41598-017-02279-x.


Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.

Juhnke M, Heumann A, Chirico V, Höflmayer D, Menz A, Hinsch A, Hube-Magg C, Kluth M, Lang DS, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, Luebke AM.

Mol Carcinog. 2017 Sep;56(9):2135-2145. doi: 10.1002/mc.22670. Epub 2017 May 22.


Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.

Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W.

Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357.


Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival.

Viehl CT, Weixler B, Guller U, Dell-Kuster S, Rosenthal R, Ramser M, Banz V, Langer I, Terracciano L, Sauter G, Oertli D, Zuber M.

Cancer Med. 2017 May;6(5):918-927. doi: 10.1002/cam4.1056. Epub 2017 Apr 12.


Pure Testicular Seminoma Relapsing Late with Somatic Type Malignancy.

Dieckmann KP, Anheuser P, Gehrckens R, Wilczak W, Sauter G, Höflmayer D.

Case Rep Oncol Med. 2017;2017:2457023. doi: 10.1155/2017/2457023. Epub 2017 Mar 7.


The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, Kirchgäßner M, Melling N, Kneisel N, Büttner R, Deuschle U, Sinn HP, Schneeweiss A, Heck S, Kaulfuss S, Hess-Stumpp H, Okun JG, Sauter G, Lykkesfeldt AE, Zapatka M, Radlwimmer B, Lichter P, Tönjes M.

Oncogene. 2017 Jul 20;36(29):4124-4134. doi: 10.1038/onc.2017.32. Epub 2017 Mar 20.


High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.

Steurer S, Rico SD, Simon R, Minner S, Tsourlakis MC, Krech T, Koop C, Graefen M, Heinzer H, Adam M, Huland H, Schlomm T, Sauter G, Lumiani A.

BJU Int. 2017 Sep;120(3):365-376. doi: 10.1111/bju.13840. Epub 2017 Apr 11.


Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.

Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, Wilczak W.

Neoplasia. 2017 Apr;19(4):279-287. doi: 10.1016/j.neo.2017.01.005. Epub 2017 Mar 8.


High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.

Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis MC, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E286. doi: 10.3390/ijms18020286.


Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2017 Jan 10;8(2):3761. doi: 10.18632/oncotarget.14557. No abstract available.


MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays.

Hinsch A, Buchholz M, Odinga S, Borkowski C, Koop C, Izbicki JR, Wurlitzer M, Krech T, Wilczak W, Steurer S, Jacobsen F, Burandt EC, Stahl P, Simon R, Sauter G, Schlüter H.

J Mass Spectrom. 2017 Mar;52(3):165-173. doi: 10.1002/jms.3916.


Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AAA, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T.

Eur Urol. 2018 May;73(5):674-683. doi: 10.1016/j.eururo.2017.01.015. Epub 2017 Jan 20.


βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F.

Hum Pathol. 2017 Mar;61:210-220. doi: 10.1016/j.humpath.2016.11.005. Epub 2016 Dec 24.


Deletion of 8p is an independent prognostic parameter in prostate cancer.

Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R.

Oncotarget. 2017 Jan 3;8(1):379-392. doi: 10.18632/oncotarget.13425.


Deletion of 18q is a strong and independent prognostic feature in prostate cancer.

Kluth M, Graunke M, Möller-Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, Simon R.

Oncotarget. 2016 Dec 27;7(52):86339-86349. doi: 10.18632/oncotarget.13404.


p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.

Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E.

Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227.


HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.

Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ.

Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887. Epub 2016 Nov 3.


Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.

Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, Lebok P.

Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1.


p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P.

Tumour Biol. 2016 Sep;37(9):12655-12663. Epub 2016 Jul 21.


Male papillary breast cancer treated by wide resection and latissimus dorsi flap reconstruction: A case report and review of the literature.

Banys-Paluchowski M, Burandt E, Banys J, Geist S, Sauter G, Krawczyk N, Paluchowski P.

World J Clin Oncol. 2016 Oct 10;7(5):420-424.


Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow.

Gunkel M, Chung I, Wörz S, Deeg KI, Simon R, Sauter G, Jones DTW, Korshunov A, Rohr K, Erfle H, Rippe K.

Methods. 2017 Feb 1;114:60-73. doi: 10.1016/j.ymeth.2016.09.014. Epub 2016 Oct 7.


HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ.

J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.


Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.

Tsourlakis MC, Stender A, Quaas A, Kluth M, Wittmer C, Haese A, Graefen M, Steurer S, Simon R, Korbel J, Weischenfeldt J, Huland H, Sauter G, Schlomm T, Minner S.

BMC Cancer. 2016 Aug 17;16:641. doi: 10.1186/s12885-016-2674-6.


CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.

Nienstedt JC, Gröbe A, Lebok P, Büscheck F, Clauditz T, Simon R, Heumann A, Sauter G, Moebius C, Münscher A, Knecht R, Blessmann M, Heiland M, Pflug C.

Clin Oral Investig. 2017 Jun;21(5):1503-1508. doi: 10.1007/s00784-016-1911-3. Epub 2016 Jul 21.


Supplemental Content

Loading ...
Support Center